Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma

Xianggui Yuan, Yurong Huang, Qunyi Guo, Yaping Xie, Nengwen Xu, Xueli Jin, Jiefeng Tong, Yun Liang, Wenbin Qian

Blood (2025) 146 (Supplement 1): 5461.

https://doi.org/10.1182/blood-2025-5461

Published: 2025

Journal Articles

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Wenbin Qian, Xuzhao Zhang, Yang Xu, Yun Liang

Blood (2025) 146 (Supplement 1): 5722.

https://doi.org/10.1182/blood-2025-5722

Published: 2025

Journal Articles

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

Xianggui Yuan, Qian Luo, Yurong Huang, Chaoyi Li, Teng Yu, Shanshan Guo, Qunyi Guo, Xueli Jin, Jiefeng Tong, Aiqi Zhao, Wen Lei, Xian Li, Baizhou Li, Shumei Wei, Wenbin Qian, Yun Liang

Blood (2025) 146 (Supplement 1): 5304.

https://doi.org/10.1182/blood-2025-5304

Published: 2025

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

Wenbin Qian, Yun Liang

Blood (2025) 146 (Supplement 1): 7215.

https://doi.org/10.1182/blood-2025-7215

Published: 2025

Journal Articles

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Wenbin Qian, Wen Lei, Hui Liu, Wei Chen, Yun Liang, Yi Eve Sun, Xiangmin Tong, Aibin Liang

Blood (2024) 144 (Supplement 1): 7209.

https://doi.org/10.1182/blood-2024-202988

Published: 2024

Journal Articles

Lenalidomide, Rituximab and Methotrexate（R2-MTX）in Newly Diagnosed Primary Central Nervous System Lymphoma

Xianggui Yuan, Yun Liang, Hui Liu, Yang Xu, Aiqi Zhao, Xiaohua Xu, Wenbin Qian

Blood (2021) 138 (Supplement 1): 2491.

https://doi.org/10.1182/blood-2021-145565

Published: 2021

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741)

Wenbin Qian, Aiqi Zhao, Hui Liu, Wen Lei, Yun Liang, Xianggui Yuan

Blood (2021) 138 (Supplement 1): 3843.

https://doi.org/10.1182/blood-2021-144523

Published: 2021

Journal Articles

Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia

Rongzhen Xu, Yingzi Yu, Shu Zheng, Xiaoying Zhao, Qinghua Dong, Zhiwen He, Yun Liang, Qinghua Lu, Yongmin Fang, Xiaoxian Gan, Xiaohua Xu, Suzhan Zhang, Qi Dong, Xiaohong Zhang, Gen-Sheng Feng

Blood (2005) 106 (9): 3142–3149.

https://doi.org/10.1182/blood-2004-10-4057

Published: 2005

Journal Articles

Mechanism of Arsenic Trioxide-Induced Apoptosis on Multiple Myeloma Cells.

Xiaohong Zhang, M.D., Yun Liang, M.D., Lida Su, M.D.

Blood (2004) 104 (11): 4904.

https://doi.org/10.1182/blood.V104.11.4904.4904

Published: 2004

Journal Articles

SHP-2 Tyrosine Phosphatase Directly Controls the Proliferative Potential of Neoplasm Cells of Human Leukemia.

Rongzhen Xu, Ph.D, Yingzi Yu, Xiaoying Zhao, Zhiwen He, Yun Liang, Xiaohong Zhang

Blood (2004) 104 (11): 4286.

https://doi.org/10.1182/blood.V104.11.4286.4286

Published: 2004

Journal Articles

Defective B-cell-negative selection and terminal differentiation in the ICF syndrome

Carla E. Blanco-Betancourt, Anne Moncla, Michèle Milili, Yun Liang Jiang, Evani M. Viegas-Péquignot, Bertrand Roquelaure, Isabelle Thuret, Claudine Schiff

Blood (2004) 103 (7): 2683–2690.

https://doi.org/10.1182/blood-2003-08-2632

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Lenalidomide, Rituximab and Methotrexate（R2-MTX）in Newly Diagnosed Primary Central Nervous System Lymphoma

Safety and Efficacy of CD19 CAR-T Cells Co-Expressing IL-7 and CCL19 in Combination with Anti-PD-1 Antibody for Refractory/Relapsed DLBCL: Preliminary Data from the Phase Ⅰb Trial (NCT04381741)

Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia

Mechanism of Arsenic Trioxide-Induced Apoptosis on Multiple Myeloma Cells.

SHP-2 Tyrosine Phosphatase Directly Controls the Proliferative Potential of Neoplasm Cells of Human Leukemia.

Defective B-cell-negative selection and terminal differentiation in the ICF syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only